Evidence map›Paper›PMID 37305699›Full record

ArticleiScience2023

Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases.

Shuangtao Zhao, Ruiping Wang, Shumei Song, Dapeng Hao, Guangchun Han, Xingzhi Song, Jianhua Zhang, Melissa Pool Pizzi, Namita Shanbhag, Andrew Futreal and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Shuangtao ZhaoGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruiping WangGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shumei SongGI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dapeng HaoGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guangchun HanGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xingzhi SongGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianhua ZhangGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Melissa Pool PizziGI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Namita ShanbhagGI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew FutrealGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brian BadgwellSurgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kazuto HaradaGI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
George CalinExperimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jody VykoukalClinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chuan-Yih YuClinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hiroyuki KatayamaClinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samir M HanashClinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Linghua WangGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jaffer A AjaniGI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Molecular dissecting and targeting YAP1 mediated cancer stemness and immune suppression in advanced gastric adenocarcinomaR01CA269685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SONG, SHUMEI · 2022 to 2025
$2.2M
NCI NIH HHS R01 CA269685
6 · The paper itself

Abstract

Advanced gastric adenocarcinoma (GAC) often leads to peritoneal carcinomatosis (PC) and is associated with very poor outcome. Here we report the comprehensive proteogenomic study of ascites derived cells from a prospective GAC cohort (n = 26 patients with peritoneal carcinomatosis, PC). A total of 16,449 proteins were detected from whole cell extracts (TCEs). Unsupervised hierarchical clustering resulted in three distinct groups that reflected extent of enrichment in tumor cells. Integrated analysis revealed enriched biological pathways and notably, some druggable targets (cancer-testis antigens, kinases, and receptors) that could be exploited to develop effective therapies and/or tumor stratifications. Systematic comparison of expression levels of proteins and mRNAs revealed special expression patterns of key therapeutics target notably high mRNA and low protein expression of HAVCR2 (TIM-3), and low mRNA but high protein expression of cancer-testis antigens CTAGE1 and CTNNA2. These results inform strategies to target GAC vulnerabilities.

Indexed as

Biological sciencesCancerGenomicsProteomics

Identifiers

PMID37305699
PMCPMC10251128
OpenAlexW4377115675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.